PROGEN acquires EuroProxima’s research antibodies

PROGEN Biotechnik GmbH expands portfolio in the cell biology market

06-Oct-2017 - Germany

PROGEN Biotechnik GmbH has recently acquired the research antibody line of the Dutch company EuroProxima B.V., a global provider of immunobiological test systems. The deal encompasses about 190 products that supplement PROGEN’s portfolio of proprietary immunochemicals.

PROGEN Biotechnik GmbH

Specific immunofluorescent labeling of skin cells with PROGEN’s keratin antibody GP-K1 (green staining)

The purchase is part of PROGEN’s expansion in the cell biology research antibody market. Dr. Sven Kuhlendahl, General Manager of PROGEN: “It is a pleasure to announce the integration of EuroProxima’s high-class antibodies into our own portfolio of over 500 antibodies. The addition of keratin and hormone antibodies in particular complement our product range substantially. We are now in an excellent position to serve research laboratories worldwide with a broad variety of immunochemical tools.”

PROGEN reaches out to potential partners in its endeavor to further expand its research reagents business. This includes monoclonal and recombinant antibodies as well as immunochemical tests supporting the validity of cell biology experiments.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous